Dr. Myron Eliot Schwartz, MD

Dr. Schwartz practices at Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida.

Dr. Schwartz's NPI, 1689640054, was assigned on February 27, 2006. Dr. Schwartz graduated from Sidney Kimmel Medical College at Thomas Jefferson University in 1976. Dr. Schwartz holds New York license 146980.

Dr. Schwartz's primary practice is Mount Sinai Medical Center, at 4300 Alton Rd, Miami Beach, FL 33140 in Miami-Dade County. The practice phone is (305) 674-2121. Dr. Schwartz also practices at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.

Dr. Schwartz's primary practice is Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida. Dr. Schwartz is also affiliated with The Mount Sinai Hospital. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Schwartz to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schwartz practices, 4 sites in all. Vendor and product names are available with a free account.

Transplant surgery is Dr. Schwartz's primary specialty in the NPI Registry, under taxonomy code 204F00000X. Dr. Schwartz is licensed in New York.

CMS data shows 339 Medicare services from Dr. Schwartz across 6 procedure codes in 2024, for 204 Medicare patients. Medicare paid $27,017 for them. Every service was in an office.

CMS counts 204 Medicare patients who saw Dr. Schwartz in 2024. The largest group is 75 to 84, with 94 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schwartz's median patient age at 68, with 43% women.

In 2024, Dr. Schwartz wrote 156 Medicare Part D claims for 47 patients. 63% of them were for generic drugs. CMS names the drug for 118 of them, across 5 drugs with 11 or more claims each, at $88,756 in total drug cost. In 2023, CMS named 112 claims across 5 drugs.

Dr. Schwartz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schwartz as offering telehealth.

Dmand AI links 187 papers to Dr. Schwartz, published from 2007 to 2025. 2020 was the busiest year, with 18. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Hepatectomy. Dr. Schwartz has published most often in HPB (Oxford). Dr. Schwartz's most frequent co-authors are Parissa Tabrizian, MD, Sasan Roayaie, MD and Sander S. Florman, MD.

Dmand AI links Dr. Schwartz to 2 clinical trials. Conditions studied include Carcinoma, Hepatocellular, Fibrosis and Liver Neoplasms.

CMS Open Payments shows 85 general payments to Dr. Schwartz from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Merck Sharp & Dohme Corporation paid the most, $23,189. It also lists 13 research payments totaling $1,993 from 2021 to 2025.

Dr. Schwartz graduated from Sidney Kimmel Medical College at Thomas Jefferson University in 1976.